Isocitrate Dehydrogenase 1 and 2 Mutations in Gliomas
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150826" target="_blank" >RIV/61989592:15110/14:33150826 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1002/jnr.23456" target="_blank" >http://dx.doi.org/10.1002/jnr.23456</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/jnr.23456" target="_blank" >10.1002/jnr.23456</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Isocitrate Dehydrogenase 1 and 2 Mutations in Gliomas
Popis výsledku v původním jazyce
Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identification of possible targets for glioma therapy. Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations have been shown to be promising biomarkers for monitoring disease prognosis and predicting the response to treatment. This review summarizes recent findings in this field. Web of Science, Science Direct, and PubMed online databases were used to search for publications investigating the roleof IDH in glioma. References were identified by searching for the keywords IDH1 or IDH2 and glioma and diagnostic or predictive or prognostic in papers published from January, 2008, to April, 2014. Only papers in English were reviewed. Publications available only as an abstract were not included. IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2-hydroxyglutarate
Název v anglickém jazyce
Isocitrate Dehydrogenase 1 and 2 Mutations in Gliomas
Popis výsledku anglicky
Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identification of possible targets for glioma therapy. Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations have been shown to be promising biomarkers for monitoring disease prognosis and predicting the response to treatment. This review summarizes recent findings in this field. Web of Science, Science Direct, and PubMed online databases were used to search for publications investigating the roleof IDH in glioma. References were identified by searching for the keywords IDH1 or IDH2 and glioma and diagnostic or predictive or prognostic in papers published from January, 2008, to April, 2014. Only papers in English were reviewed. Publications available only as an abstract were not included. IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2-hydroxyglutarate
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EB - Genetika a molekulární biologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
JOURNAL OF NEUROSCIENCE RESEARCH
ISSN
0360-4012
e-ISSN
—
Svazek periodika
92
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
1611-1620
Kód UT WoS článku
000344004500002
EID výsledku v databázi Scopus
—